generic launches and risk mitigation

34
GENERIC LAUNCHES AND RISK MITIGATION Supriya Ramacha Copyright 2012 BananaIP Website: www.bananaip.com Blog: www.bananaip.com/sinapse-blog

Upload: bananaip-counsels

Post on 08-May-2015

135 views

Category:

Law


2 download

DESCRIPTION

Generic Launches and Risk Mitigation

TRANSCRIPT

Page 1: Generic Launches and Risk Mitigation

GENERIC LAUNCHES AND RISK MITIGATION

Supriya Ramacha

Copyright 2012 BananaIP

Website: www.bananaip.comBlog: www.bananaip.com/sinapse-blog

Page 2: Generic Launches and Risk Mitigation

AGENDA

Product launch

Risks in product launch

Risk mitigation strategies

Page 3: Generic Launches and Risk Mitigation

PRODUCT LAUNCH - GENERIC

Page 4: Generic Launches and Risk Mitigation

PRODUCT LAUNCH

Risk free routePatent expiryWork around

At-risk routeChallenge/Infringe

Page 5: Generic Launches and Risk Mitigation

RISKS IN PRODUCT LAUNCHES

Page 6: Generic Launches and Risk Mitigation

BACKGROUND

Patent Rights

Make

Use

Sell

Offer for sale

Import

Territorial

Term

Page 7: Generic Launches and Risk Mitigation

PATENT RISKS

Standard Patent Term

Term extensionsPatent office delaysRegulatory delays

Page 8: Generic Launches and Risk Mitigation

US-TERM EXTENSIONS

Patent process-Patent term adjustments (PTA)

One day extension - every day delayedObjective = 17 years

TypesA delays (failure to act-14-4-4-4 rule)B delays (pendency beyond 3 years)C delays (special situation)

Page 9: Generic Launches and Risk Mitigation

EXAMPLE

Billy owns a US patent application for a drug “X” filed on Jan 1st 2002, for which he receives the first office action on June 1st 2003. The patent is issued on Jan 1st 2005. Silly, a generic drug maker, wants to launch “Y,” the generic version of the drug.

Launch date?

Page 10: Generic Launches and Risk Mitigation

Bopi files a US patent application for a drug “Alpha” filed on Jan 1st 1998, for which it receives the first office action on June 1st 2000. The patent is issued on Jan 1st 2005. Dopi, a generic drug maker, wants to launch “Beta,” the generic version of the drug.

PTA?

Page 11: Generic Launches and Risk Mitigation

EXAMPLE

Billy’s application for a drug “X” filed on Jan 1st 2002 receives the first office action on June 1st 2003.

Billy’s patent is issued on March 1st 2007 after paying the issue fee on Sept 1st 2006

Silly’s Launch date ?

Wyeth Vs Kappos case

Page 12: Generic Launches and Risk Mitigation

PATENT TERM EXTENSIONS

Regulatory process-Patent term extensions (PTE)1/2 Testing phase + Approval phase

Calculationmax of 5 years extensionNMT 14 years of potential marketing exclusivity

Page 13: Generic Launches and Risk Mitigation

EXAMPLE Mandoz files for a US patent on “Mentos” on April 1st

2000. The patent is issued on July 1st 2002. It subsequently files an IND application effective on July 1st 2003.

Mandoz files an NDA on July 1st 2005 and receives approval on July 1st 2006.

Possible extension? Actual extension? Launch date?

Page 14: Generic Launches and Risk Mitigation

PTEs depends on the no. of potential exclusive marketing term available.

Page 15: Generic Launches and Risk Mitigation

EXAMPLE Mandoz files for a US patent on “Mentos” on April 1st

2000. It files an IND application effective on July 1st 2002. The patent was issued on July 1st 2003.

Mandoz files for an NDA on July 1st 2005 and receives NDA approval on July 1st 2006.

Possible extension? Actual extension? Launch date?

Sprycel Tablets, Dasatinib,US6596746

Page 16: Generic Launches and Risk Mitigation

PTE

CalculationDoes not include anytime before the date of patent

issue

Total patent term= Standard patent term + PTA + PTE

Page 17: Generic Launches and Risk Mitigation

EUROPE

Regulatory process- Supplementary protection certificate (SPC)SPC Term= (1st MA date - patent filing date) - 5

years.territorial

Calculation5 years max (+6 months)NMT 15 years of potential marketing exclusivity

Total patent term = Standard Patent term + SPC

Page 18: Generic Launches and Risk Mitigation

EXAMPLE

Dizer, a French applicant, obtains a national marketing approval on Jan 1st 2000, for a product protected by a patent with the filing date of Jan 1st 1990.

Dizer has also received a marketing approval in Britain on Jan 1st 1997.

Launch date?

Page 19: Generic Launches and Risk Mitigation

EXAMPLE

Banana & Co. files for a patent in France on Jan 1st 1998 for a drug “Todi” and receives a national marketing approval on Jan 1st 2001. It also files for a patent in Spain on Jan 1st 1999 and receives a marketing approval in Spain on Jan 1st 2000.

Launch date in France?

Page 20: Generic Launches and Risk Mitigation

REGULATORY HURDLES IN GENERIC LAUNCH

Copyright 2012 Brain League

Page 21: Generic Launches and Risk Mitigation

REGULATORY HURDLES

Regulatory exclusivitiesData exclusivityOther exclusivity

Page 22: Generic Launches and Risk Mitigation

US EXCLUSIVITIES

Data exclusivity- 5 years

(+1.5 to 2 years) Other exclusivity-

New clinical study exclusivity-3 yearsOrphan drug exlusivity-7 yearsPediatric exclusivity-6 months

Page 23: Generic Launches and Risk Mitigation

EUROPE

Currently- 6 or 10 years

(+1 to 3 years)

New- 8+2+1 regime

Current- (2001/83/EC Directive) New- (2001/83/EC Directive as amended by 2004/27/EC)

Page 24: Generic Launches and Risk Mitigation
Page 25: Generic Launches and Risk Mitigation

RISK MITIGATION STRATEGIES

Page 26: Generic Launches and Risk Mitigation

RISK MITIGATION STRATEGIES

Risk free launchesIdentify blocking patents- FTO analysisUnderstanding expiry

Infringement/ ChallengingIdentify evidences – Invalidation

Work aroundTechnology Landscaping

Page 27: Generic Launches and Risk Mitigation

FTO ANALYSIS

Copyright 2012 Brain League

Page 28: Generic Launches and Risk Mitigation

EVALUATE FTO

Search

Patent databases-blocking patent/application

Analysis

Infringement

Page 29: Generic Launches and Risk Mitigation

ANALYSIS

Infringement factors

Territorial

Term

Claims

Page 30: Generic Launches and Risk Mitigation

TECHNOLOGY LANDSCAPE ANALYSIS

Page 31: Generic Launches and Risk Mitigation
Page 32: Generic Launches and Risk Mitigation

© 2

01

1 In

telle

cture

(w

ww

.inte

llectu

rein

dia

.com

)

Page 33: Generic Launches and Risk Mitigation

TECHNOLOGY MAP

Page 34: Generic Launches and Risk Mitigation

THANK YOUFOR MORE DETAILS VISIT

WWW.BANANAIP.COM/SINAPSE-BLOG

A Property of BananaIP